Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032924) SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/032924 International Application No.: PCT/US2018/046146
Publication Date: 14.02.2019 International Filing Date: 09.08.2018
IPC:
C07C 275/28 (2006.01) ,C07C 275/30 (2006.01) ,A61K 31/17 (2006.01) ,A61P 25/00 (2006.01) ,A61P 25/16 (2006.01) ,A61P 25/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
275
Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
28
having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
275
Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
28
having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
30
being further substituted by halogen atoms, or by nitro or nitroso groups
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
17
having the group N-C(O)-N or N-C(S)-N, e.g. urea, thiourea, carmustine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants:
TEXAS TECH UNIVERSITY SYSTEM [US/US]; Office Of Technology Comercialization Box 42007 Lubbock, TX 79409-2007, US
Inventors:
CONSTANTINOS, Mikelis; US
GERMAN, Nadezhda; US
Agent:
ANDERSON, Kristopher, Lance; US
DICKINSON WRIGHT PLLC; International Square 1825 Eye St. N.w., Suite 900 Washington, DC 20006, US
Priority Data:
62/543,33609.08.2017US
Title (EN) SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS
(FR) COMPOSÉS DE BISPHÉNYLALKYLURÉE SUBSTITUÉS ET PROCÉDÉS
Abstract:
(EN) Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, HI receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.
(FR) L'invention concerne une composition et un procédé pour un traitement thérapeutique qui est capable de lutter contre une neuroinflammation provoquée par des maladies et des troubles tels que la maladie d'Alzheimer, la maladie de Parkinson et une lésion cérébrale traumatique. Ce type de composés d'urée agit par blocage au niveau de récepteurs ciblés, présents dans le cerveau et qui contribuent à renforcer l'inflammation. Des combinaisons de récepteurs, le récepteur HI, le récepteur H2, le transporteur de dopamine (DAT) et/ou le récepteur 5HT3C, sont inhibés individuellement et/ou collectivement par les compositions mêmes de la présente invention, et cette capacité conduit à une diminution de l'œdème cérébral. Les effets inhibiteurs du DAT contribuent en outre à préserver les niveaux de dopamine chez un patient.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)